Dr. Doyle is a proven research physician who brings over 20 years of experience in the pharmaceutical/biotech industry and academia. She previously served on the Board of Directors of DICE Therapeutics (Nasdaq:DICE) which was acquired by Eli Lilly and Company. She has held numerous leadership roles in Clinical Development throughout her career. She currently serves as Chief Medical Officer of Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines. Prior to joining Aro, Dr. Doyle was Vice President, Global Therapeutic Area Head, Immunology at CSL Behring. Dr. Doyle has held senior level roles at Shire Pharmaceuticals, Flexion Therapeutics and Alexion Pharmaceuticals. During her career, she has advanced assets across a broad range of immune-mediated and orphan diseases and led teams with responsibilities for design and execution of first-in-human through Phase 2 and 3 trials, resulting in several global regulatory approvals. Dr. Doyle earned her M.D. from Yale Medical School cum laude and completed her postdoctoral training at Harvard Medical School including internship and residency in Internal Medicine at Massachusetts General Hospital and a postdoctoral fellowship in Rheumatology and Immunology at Brigham and Women’s Hospital. She received her B.A. magna cum laude in Romance Languages and Literatures from Princeton University.